阿法替尼致表皮生长因子受体突变型非小细胞肺癌相关性低血压：病例报告及文献复习。
Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review.
机构信息
Department of Pulmonary & Critical Care Medicine, Affiliated Yixing People's Hospital, Jiangsu University, Yixing.
Department of Oncology, Affiliated Taicang Hospital of Traditional Chinese Medicine, Taicang, China.
出版信息
Anticancer Drugs. 2022 Jan 1;33(1):e840-e841. doi: 10.1097/CAD.0000000000001244.
Side effects of afatinib are a problem in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of afatinib-induced hypotension. An 81-year-old man with NSCLC had an epidermal growth factor receptor-positive genotype with the p.L861Q mutation in exon 21. He was administered afatinib (40 mg/day) as anticancer therapy. Hypotension occurred twice after afatinib initiation. He suffered from dizziness and nausea. Blood pressure gradually returned to normal after afatinib cessation. Clinicians should be aware of hypotension in patients with NSCLC after afatinib initiation.
阿法替尼的副作用是晚期非小细胞肺癌（NSCLC）患者的一个问题。然而，对于阿法替尼引起的低血压的发生知之甚少。一名 81 岁男性 NSCLC 患者存在表皮生长因子受体阳性基因型，第 21 外显子 p.L861Q 突变。他接受阿法替尼（40 mg/天）作为抗癌治疗。阿法替尼起始后发生了 2 次低血压。他出现头晕和恶心。阿法替尼停药后血压逐渐恢复正常。临床医生应注意阿法替尼起始后 NSCLC 患者的低血压。
Zotero 插件